Claim Amendments:

Claim 1. (Currently amended): A solid pharmaceutical composition <u>in tablet form</u> for oral administration comprising a benzofuran derivative with antiarrhythmic activity, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant <u>selected from poloxamers</u>, optionally in combination with one or more pharmaceutical excipients, said nonionic hydrophilic surfactant being present in a proportion of from <u>5% to 15% 1% to 50%</u> by weight of the active principle in base form, provided that the pharmaceutical composition does not contain a polysorbate surfactant.

Claim 2. (Previously presented): A pharmaceutical composition according to Claim 4, wherein the benzofuran derivative is dronedarone hydrochloride.

Claim 3. (Previously presented): A pharmaceutical composition according to Claim 4, wherein the benzofuran derivative is amiodarone hydrochloride.

Claim 4. (Previously presented): A pharmaceutical composition according to Claim 14 wherein the pharmaceutically acceptable salt is the hydrochloride.

Claim 5. (Canceled)

Claim 6. (Currently amended): A pharmaceutical composition according to <u>Claim 1 Claim 5</u> wherein the nonionic hydrophilic surfactant is selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, <u>and poloxamer 407, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and the products Cremophor®RH 40 and Solutol®-HS15.</u>

Claim 7. (Previously presented): A pharmaceutical composition according to Claim 15 wherein the nonionic hydrophilic surfactant is poloxamer 407.

Claims 8-10 (Canceled)

Claim 11. (Previously presented): A pharmaceutical composition according to Claim 6 containing from 50 to 500 mg of active principle.

Claim 12. (Currently amended): A pharmaceutical composition according to Claim 11,-in tablet or gelatin capsule form, containing from 200 to 400 mg of active principle.

Claim 13. (Currently amended): A pharmaceutical composition according to Claim 12, in tablet or gelatin capsule form, containing from 200 to 400 mg of active principle, calculated in base form, and 10% by weight of nonionic hydrophilic surfactant relative to the active principle in base form.

Claim 14. (Previously presented): A pharmaceutical composition according to Claim 1 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.

Claim 15. (Previously presented): A pharmaceutical composition according to Claim 6 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.

Claim 16. (Previously presented): A pharmaceutical composition according to Claim 7 wherein the benzofuran derivative is dronedarone hydrochloride.

Claim 17. (Canceled)

Claim 18. (Currently amended): A pharmaceutical composition according to <u>Claim 6 Claim 17</u> wherein the nonionic hydrophilic surfactant is poloxamer 407.

Claim 19. (Previously presented): A pharmaceutical composition according to Claim 18 wherein the benzofuran derivative is dronedarone hydrochloride.

Claim 20. (Previously presented): A pharmaceutical composition according to Claim 13 wherein the active principle is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.

Claim 21. (Previously presented): A pharmaceutical composition according to claim 20 wherein the nonionic hydrophilic surfactant is poloxamer 407.

Claim 22. (Previously presented): A pharmaceutical composition according to claim 21 wherein the active principle is dronedarone hydrochloride.